We also found that the amplification rates of PRKDC were significantly higher in AMs and MMs than in CMs (49% in AMs, 63% in MMs and 18% in CMs) and were confirmed to be associated with patient clinical outcomes in all three histological types of melanomas, consistent with previous studies12,32,33 (Supplementary Fig. S3b, c). Here, PRKDC is linked to melanoma.